As of Friday's close, ONCY had 4 analyst targets pointing to a significant amount of upside potential.
In fact, with an average target of $8.50, ONCY could have over 800% potential upside from its closing valuation on the 10th.
MarketBeat reports further that Patrick R. Trucchio of H.C. Wainwright has given ONCY a $10 target representing a potential upside over 1,000% from Friday's close.
Could (Nasdaq: ONCY) be undervalued from current chart levels? -----
#2. ONCY Potential Catalyst - A New Patent Secured (Protect Company's Proprietary Manufacturing Process).
Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044
Intellectual property update confirms pelareorep's unique manufacturing process and scalability
Previously filed method-of-use patent application expected to provide protection into 2046
Additional patent filings planned in 2026 to further expand the pelareorep intellectual property estate
SAN DIEGO, June 16, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), ..., today announced that the United States Patent and Trademark Office ("USPTO") has issued a new patent broadly protecting the Company's proprietary manufacturing process for pelareorep.
The newly issued patent covers key aspects of the methods used to manufacture pelareorep and is expected to provide intellectual property protection into 2044. The patent is designed to protect the Company's ability to consistently produce pelareorep at commercial scale and represents a significant addition to Oncolytics' growing intellectual property portfolio.
...
"Building a strong intellectual property estate around pelareorep is an important part of our strategy as we advance the program toward potential registration and commercialization," said Jared Kelly, Chief Executive Officer of Oncolytics. "This newly issued patent strengthens our protection around the manufacturing of pelareorep and supports our ability to produce the product at commercial scale. Combined with our previously filed method-of-use patent application and additional planned filings, we continue to build a durable patent portfolio designed to support the long-term value of pelareorep. Checking this box represents another important milestone as we execute on our strategy and move pelareorep into its next phase of development."
...
Read the full article here. -----
#3. ONCY Potential Catalyst - Initial Preclinical Data Demonstrates Evidence Of Greater Anti-Tumor Activity.
Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
Early results from solid tumor model support additional studies in pancreatic and colorectal cancer models; full dataset planned for presentation later in 2026
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, today announced initial data from a preclinical study evaluating pelareorep in combination with RAS inhibitor modalities in a solid tumor model, which demonstrate evidence of greater anti-tumor activity in combination than with the individual approaches alone. Pelareorep is an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes.
Based on these findings, the Company is planning additional studies in models of pancreatic ductal adenocarcinoma ("PDAC") and colorectal cancer ("CRC") designed to further evaluate the combinations' effects on immune activation, tumor response durability, and time-to-resistance. The ongoing work includes evaluations of pelareorep in combination with KRAS G12C inhibitors, pan-RAS inhibitors, and additional next-generation RAS pathway-targeting agents in RAS-mutated tumor models.
"We believe these initial findings further support pelareorep's potential to serve as an immune-priming backbone for next-generation targeted therapies," said Jared Kelly, Chief Executive Officer of Oncolytics. "RAS-mutated tumors, particularly pancreatic and colorectal cancers, remain among the most difficult cancers to treat due to intrinsic immune resistance and the emergence of therapeutic resistance over time. These preclinical results support further study of the combinations' anti-tumor and immune effects, including in models designed to assess durability and time-to-resistance."
Mr. Kelly continued, "Importantly, we believe this strategy may ultimately represent a potentially important area for further investigation in pancreatic cancer, where nearly all tumors harbor RAS pathway alterations and where patients continue to face extremely limited treatment options. The potential synergy observed in previous PDAC clinical studies and preclinical RAS-targeted modalities reinforces our belief that pelareorep may play an important role in future combination strategies designed to improve the durability of targeted therapies."
...
Read the full article here. -----
#4. ONCY Potential Catalyst - The Company Adds Significant Experience To Their Board Of Directors (Promotes New COO).
Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), ..., today announced the appointment of Steve Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer ("COO").
Mr. Glover brings significant public company leadership and transaction experience to Oncolytics, including serving as Chairman of Ambrx Biopharma during its acquisition by Johnson & Johnson in a transaction valued at approximately $2Bn.
Additionally, Mr. McAdory has been promoted to Chief Operating Officer. As COO, he will oversee the Company's clinical operations and development activities, preclinical research and development efforts, and will play a key role in strategic partnerships and broader business development initiatives. Mr. McAdory joined Oncolytics earlier this year after serving as VP of Clinical Operations at CG Oncology.
"We are thrilled to welcome Steve to our Board at a transformational time for Oncolytics," said Jared Kelly, Chief Executive Officer of Oncolytics. "Steve has extensive experience helping build and position innovative biotechnology companies for strategic growth and value creation, including through the successful sale of Ambrx to Johnson & Johnson. His experience across corporate strategy, financing, and strategic transactions will be invaluable as we continue to advance pelareorep and expand our immunotherapy platform strategy."
Mr. Kelly continued, "I am also very excited to announce John's promotion to Chief Operating Officer. Since joining Oncolytics, John has already had a meaningful impact on our operational execution and clinical development strategy. His background helping advance innovative oncology programs at CG Oncology and his strong operational leadership make him ideally suited to help drive our next phase of growth as we advance our registration-enabling studies, expand our preclinical pipeline, and pursue strategic partnership opp's."
"I am excited to join the Board of Oncolytics during this important period of clinical and corporate momentum," said Mr. Glover. "I believe pelareorep has the potential to become an important immunotherapy backbone across multiple solid tumor indications, and I look forward to working with the management team and Board to help maximize the platform's value."
"I appreciate the confidence the Board and leadership team have placed in me," said John McAdory, Chief Operating Officer of Oncolytics. "I believe Oncolytics is uniquely positioned with compelling clinical and translational data, particularly in gastrointestinal cancers, and I look forward to helping accelerate and execute on the Company's developmental, operational, and strategic objectives."
Read the full article here. -----
#5. ONCY Potential Catalyst - A Zacks Small-Cap Research Analyst Chimes In With A $6 Target For ONCY.
Another analyst, David Bautz of Zacks Small-Cap Research, has shared a $6.00 target as of mid-May.
From its 4:00PM EST close on Friday, that targets suggests 550+% potential upside for ONCY.
Report highlights:
We look forward to additional details on the upcoming pivotal trial for pelareorep in anal cancer, for which we continue to anticipate it initiating in the second half of 2026. The updated response data for pelareorep in mCRC is very encouraging, and we look forward to updates from the company regarding the potential for accelerated approval in that indication. With no changes to our model, our valuation remains at $6 per share. -----
(Nasdaq: ONCY) Recap - 5 Potential Catalysts Hits Our Radar
#1. An Average Of 4 Analyst Targets Suggest Major Upside Potential (Triple-Digit).
#2. A New Patent Secured (Protect Company's Proprietary Manufacturing Process).
#3. Initial Preclinical Data Demonstrates Evidence Of Greater Anti-Tumor Activity.
#4. The Company Adds Significant Experience To Their Board Of Directors (Promotes New COO).
#5. A Zacks Small-Cap Research Analyst Chimes In With A $6 Target For ONCY. -----
Coverage is now underway on Oncolytics Biotech Inc. (Nasdaq: ONCY).
Updates will be coming out soon. Keep your eyes peeled.
Sincerely, Kai Parker StockWireNews
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 07/12/2026 and ending on 07/13/2026 to publicly disseminate information about (ONCY:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC twenty thousand USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid sixty thousand USD ("Funds"). These Funds were part of the one hundred thousand USD funds that TD Media LLC received from Oncolytics Biotech Inc., the issuer of (ONCY:US).
Neither SWN Media LLC, TD Media LLC and their member own shares of (ONCY:US).
Please see important disclosure information here: https://stockwirenews.com/disclosure/oncy-rzcki/#details |
